目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T12607 | Antibacterial Antibiotic | ||
Quinupristin 是一种链球菌素类抗生素,可阻断细菌核糖体亚基中的肽键合成,阻止多肽链的延伸,促进不完全蛋白链的分离。 | |||
T37988 | |||
D-Ribulose-5-phosphate is an intermediate in the pentose phosphate pathway. [1][2] It can be derived from 6-phosphogluconate by a dehydrogenase or from xylulose 5-phosphate by ribulose phosphate 3-epimerase. D-Ribulose-5-phosphate is also an intermediate in carbon fixation in photosynthetic organisms as well as in the biosynthesis of lipopolysaccharide, amino acids, secondary metabolites, and antibiotics.[3] | |||
T74864 | |||
TL4830031 (compound 8i) 是一种喹诺酮类抗生素衍生物,是一种有效的 Axl 抑制剂,其 IC50值为 26 nM。TL4830031 抑制 Axl 的磷酸化。TL4830031 抑制细胞侵袭和迁移。TL4830031 可用于癌症研究。 | |||
T76071 | |||
Epinecidin-1 TFA, 一种从橙斑石斑鱼 (Epinephelus coioides) 提取的多功能抗菌肽 (AMP),展现了抗菌、抗真菌、抗病毒、抗肿瘤及免疫调节等多重生物活性,有望作为当前抗生素的替代品。 | |||
T37008 | |||
Reveromycin A is the major component of a complex of spiroketal antibiotics isolated from Streptomyces sp. It inhibits the mitogenic activity of epidermal growth factor in Balb/MK cells (IC50 = 0.7 μg/ml), displays antiproliferative activity against human KB and K562 tumor cell lines (IC50s = 1.9 and 1.6 μg/ml, respectively), and demonstrates antifungal activity against C. albicans (MIC = 2 μg/ml at pH 3). Reveromycin A also has been shown to inhibit bone resorption by inducing apoptosis in osteoclasts with an IC50 value of 0.7 μM. | |||
T36474 | |||
TunR1 is an antibiotic and derivative of tunicamycin .1It is active againstB. subtilis(MIC = 0.3 μg/ml) and increases the efficacy of the β-lactam antibiotics oxacillin , methicillin , and penicillin G againstB. subtiliswhen used at a concentration of 0.4 μg/ml. TunR1 (5 μg/ml) is cytotoxic to MDA-MB-231 breast cancer cells and non-cancerous CHO cells. Unlike tunicamycin, TunR1 does not inhibit glycosylation in a protein N-glycosylation assay. 1.Price, N.P., Hartman, T.M., Li, J., et al.Modified tunicamycins with reduced eukaryotic toxicity that enhance the antibacterial activity of β-lactamsJ. Antibiot. (Tokyo)70(11)1070-1077(2017) | |||
T37465 | |||
CAY10742 is an orally bioavailable oxadiazole antibiotic.1It is active against the Gram-positive bacteriaS. aureus,S. epidermidis,S. haemolyticus,B. cereus,B. licheniformis,E. faecalis, andE. faecium(MICs = 1-4 μg/ml), including laboratory strains and clinical isolates with varying degrees of resistance to methicillin, vancomycin, linezolid, and other antibiotics. CAY10742 (40 mg/kg) reduces the number of bacteria in mouse neutropenic thigh models of linezolid-sensitive or -resistant methicillin-resistantS. aureus(MRSA) infection. 1.Boudreau, M.A., Ding, D., Meisel, J.E., et al.Structure-activity relationship for the oxadiazole class of antibacterialsMed. Chem. Lett.11(3)322-326(2019) | |||
T74529 | |||
Antibacterial agent 86 (Compound A11) 活性较强,对耐甲氧西林金黄色葡萄球菌具有抑菌活性,MIC 值低至 0.00191 μg/mL,比市售抗生素泰妙菌素和瑞他莫林分别低 162 倍和 32 倍。 | |||
T37408 | |||
Bacterial type II fatty acid synthesis (FAS-II) is mediated by a series of enzymes, each of which may be targeted by potential antibiotics. Bischloroanthrabenzoxocinone (BABX) is an inhibitor of FAS-II, blocking fatty acid synthesis in S. aureus and E. coli with IC50 values of 11.4 and 35.3 μg/ml, respectively. It inhibits the growth of S. aureus and permeable E. coli strains with minimum inhibitory concentrations ranging from 0.2-0.4 μg/ml. BABX also displays binding to liver X receptors (LXRs), inhibiting agonist binding in an LXRα-scintillation proximity assay (IC50 = 10 μM). | |||
T77238 | |||
Fmoc-L-photo-proline为可通过Fmoc固相法纳入合成肽中的光交联氨基酸。该化合物在环状拟肽抗生素合成及肽基光亲和探针研究制备中应用广泛。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPH-02373 | Metallo-beta-lactamase type 2 Protein, Klebsiella pneumoniae, Recombinant (His) | Klebsiella pneumoniae | E. coli | ||
Confers resistance to the different beta-lactams antibiotics (penicillin, cephalosporin and carbapenem) via the hydrolysis of the beta-lactam ring. Does not confer resistance to the polymixin colistin or the fluoroquinolone ciprofloxacin.
|
|||||
TMPH-03488 | Metallo-beta-lactamase type 2 Protein, Serratia marcescens, Recombinant (His & Myc) | Serratia marcescens | E. coli | ||
Confers resistance to the different beta-lactams antibiotics (penicillin, cephalosporin and carbapenem) via the hydrolysis of the beta-lactam ring. Metallo-beta-lactamase type 2 Protein, Serratia marcescens, Recombinant (His & Myc) is expressed in E. coli expression system with N-10xHis and C-Myc tag. The predicted molecular weight is 32.6 kDa and the accession number is P52699.
|
|||||
TMPH-00587 | Beta-lactamase TEM Protein, E. coli, Recombinant (His & SUMO) | E. coli | E. coli | ||
TEM-type are the most prevalent beta-lactamases in enterobacteria; they hydrolyze the beta-lactam bond in susceptible beta-lactam antibiotics, thus conferring resistance to penicillins and cephalosporins. TEM-3 and TEM-4 are capable of hydrolyzing cefotaxime and ceftazidime. TEM-5 is capable of hydrolyzing ceftazidime. TEM-6 is capable of hydrolyzing ceftazidime and aztreonam. TEM-8/CAZ-2, TEM-16/CAZ-7 and TEM-24/CAZ-6 are markedly active against ceftazidime. IRT-4 shows resistance to beta-lactamase inhibitors.
|
|||||
TMPH-00586 | Beta-lactamase TEM Protein, E. coli, Recombinant (His) | E. coli | P. pastoris (Yeast) | ||
TEM-type are the most prevalent beta-lactamases in enterobacteria; they hydrolyze the beta-lactam bond in susceptible beta-lactam antibiotics, thus conferring resistance to penicillins and cephalosporins. TEM-3 and TEM-4 are capable of hydrolyzing cefotaxime and ceftazidime. TEM-5 is capable of hydrolyzing ceftazidime. TEM-6 is capable of hydrolyzing ceftazidime and aztreonam. TEM-8/CAZ-2, TEM-16/CAZ-7 and TEM-24/CAZ-6 are markedly active against ceftazidime. IRT-4 shows resistance to beta-lactamase inhibitors.
|
|||||
TMPY-01812 | Enoyl-ACP Reductase Protein, E. coli, Recombinant (His) | E. coli | E. coli | ||
Enoyl-ACP reductase, also known as NADH-dependent enoyl-ACP reductase and FABI, is a cell inner membrane and peripheral membrane protein which belongs to theshort-chain dehydrogenases/reductases (SDR) family and FabI subfamily. Microorganisms produce many kinds of antibiotics which function in an antagonistic capacity in nature where they have much competition. Bacterial FAS provides essential fatty acids for use in the assembly of key cellular components. Among them, FABI is an enoyl-ACP reductase which catalyzes the final and rate-limiting step of bacterial FAS. The antibiotic diazaborine interferes with the activity by binding to the protein. FABI is a potential target for selective antibacterial action, because it shows low overall sequence homology with mammalian enzymes. Various compounds have been reported as inhibitors of bacterial FabI-inhibitory compounds.
|